Spero Therapeutics (MEX:SPRO) Unearned Premiums

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SPRO Spero Therapeutics Inc MEX:SPRO
40 GF Score
Price MXN20.74
GF Value MXN13.54
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Spero Therapeutics Unearned Premiums?

Unearned Premiums only applies to insurance companies.

MEX:SPRO
40GF Score
Spero Therapeutics Inc MEX:SPRO
Unearned Premiums is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Spero Therapeutics (MEX:SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of MXN20.74 is trading 53.2% above its estimated GF Value™ of MXN13.54. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for MEX:SPRO:

  • Unearned Premiums:
  • GF Value™: MXN13.54 vs. price of MXN20.74 (53.2% above fair value)
  • GF Score™: 40/100 with 2 warning signs

No single metric tells the full story. See the MEX:SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spero Therapeutics Business Description

Comparable Companies
Other Exchanges SPRO:USA2HA:Germany
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
40GF Score

Get the complete analysis for MEX:SPRO

Unearned Premiums is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN20.74
Price
MXN13.54
GF Value